Grifols, S.A. (GRFS) vs Sanofi (SNY)
Grifols, S.A. and Sanofi are both Drug Manufacturers General companies. Sanofi is the larger, with a market value of $97.4B against $1.9B — 52.4× the size. Grifols, S.A. trades at the lower P/E: 8.1× against 21.5×. Sanofi grew revenue faster over the last twelve months: 21.3% against 16.0%. Sanofi has the higher net margin (8.22% vs 5.54%) and the higher return on invested capital (6.58% vs 0.00%). Both pay a dividend; Sanofi yields more (4.40% vs 0.15%). Across the 23 metrics below, Grifols, S.A. leads on 12 and Sanofi on 11.
Valuation
Profitability
| Metric | GRFS | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.45% | 72.78% | 72.77% |
| Operating margin | 16.43% | 18.24% | 18.90% |
| Net margin | 5.54% | 8.22% | 8.27% |
| Free cash flow margin | 0.00% | 25.53% | 17.25% |
| Return on equity | 0.00% | 5.87% | 6.97% |
| Return on assets | 0.00% | 3.21% | 2.76% |
| Return on invested capital | 0.00% | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack